Impact of IL-2 on Treatment Tolerance in Patients With High-Risk Neuroblastoma Treated With Dinutuximab Beta-Based Immunotherapy

Impact of IL-2 on Treatment Tolerance in Patients With High-Risk Neuroblastoma Treated With Dinutuximab Beta-Based Immunotherapy

Patients with high-risk neuroblastoma treated with continuous long-term infusion of anti-GD2 antibody dinutuximab beta (DB) in combination with IL-2 show an acceptable safety profile. Here, we compared treatment tolerance with and without IL-2. Ninety-nine patients with high-risk neuroblastoma recei...

Full description

Bibliographic Details
Main Authors: Filiz Cicek, Sascha Troschke-Meurer, Kiraz Ceylan, Luciana J. Jahns, Maxi Zumpe, Nikolai Siebert, Karoline Ehlert, Holger N. Lode
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-12-01
Series:Frontiers in Pediatrics
Subjects:
dinutuximab beta
immunotherapy
interleukin 2
neuroblastoma
toxicity
treatment tolerance
Online Access:https://www.frontiersin.org/articles/10.3389/fped.2020.582820/full

Similar Items

Similar Items